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Neonatal desensitisation for the study of regenerative medicine 1 
Summary 2 
Cell replacement is a therapeutic option for numerous diseases of the central nervous system (CNS). 3 
Current research has identified a number of potential human donor cell types, for which pre-clinical 4 
testing through xenotransplantation in animal models is imperative. Immune modulation is 5 
necessary to promote donor cell survival for sufficient time to assess safety and efficacy. Neonatal 6 
desensitisation can promote survival of human donor cells in adult rat hosts with little impact on the 7 
health of the host and for substantially longer than conventional methods, and has subsequently 8 
been applied in a range of studies with variable outcomes. Reviewing these findings may provide 9 
insight into the method and its potential for use in pre-clinical studies in regenerative medicine. 10 
Keywords: Transplantation, rodent models, cell replacement, Huntington’s disease, 11 
immunosuppression, xenograft, desensitisation, rejection 12 
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Why is long term assessment of human neural grafts in rodent hosts needed? 14 
Regenerative medicine seeks to provide therapies for a wide range of diseases that are associated 15 
with the loss or dysfunction of a specific population of cells. Two candidate neurological conditions 16 
with relatively focussed loss of specific neuronal populations are Parkinson’s disease (PD), in which 17 
there is loss of dopaminergic projection neurons in the substantial nigra, and Huntington’s disease 18 
(HD) in which there is loss of medium spiny projection neurons (MSNs) from the striatum. 19 
Implantation of primary foetal cells (PFCs) taken directly from the developing brain has provided 20 
proof of concept that transplantation has the potential to be an effective therapeutic option in PD 21 
and HD in both animal [1-3] and clinical studies [4, 5]. However, PFCs are not a practical option for 22 
routine use in the clinic for several reasons. In particular, in order to implant sufficient cells of a 23 
specific striatal or dopaminergic phenotype several foetal donors are necessary for each patient 24 
(potentially up to 6 in HD, and 8-12 in PD) [6, 7]. As storage of PFCs prior to transplantation is 25 
currently limited to a maximum of 8 days in hibernation medium [8], clinical transplantation relies 26 
on the availability of sufficient donor tissue within this time window. Furthermore, as patients 27 
receive transplants from different foetal donors, issues can arise with the variability and purity of the 28 
cells that may affect the success of the transplants [7, 9, 10]. Additionally, the risk of a graft 29 
containing cells that are immunologically incompatible is raised (see below).  30 
Thus, as well as refining the transplantation methodology, current research aims to identify sources 31 
of potential donor cells that will offer a practical alternative to PFCs; which is most likely to be one or 32 
more of the stem cell sources [11]. It will be important that such cells can produce large stable 33 
populations of clinical grade cells that can be quality controlled and standardised across transplants.  34 
However, an equally important requirement of donor cells is that they are able to recapitulate the 35 
precise features of the cells that have been lost to the disease process [12]. For example, for PD this 36 
requires the transplantation of cells which can not only generate a dopaminergic phenotype, but will 37 
specifically become dopamine cells of the A9 midbrain phenotype. For HD, this means generating 38 
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cells of a MSN phenotype that possess all the features of the native cells which arise from the foetal 39 
whole ganglionic eminence (WGE) and are able to make appropriate synaptic connections post 40 
transplantation. Not surprisingly, developing effective protocols that achieve this and can be 41 
translated for GMP (good manufacturing practice) cell production is difficult and usually requires 42 
months/years of protocol refinements in vitro for a single cellular phenotype.   Although it is possible 43 
to use cellular markers in vitro to assess several aspects of the differentiated cellular phenotype, 44 
ultimately it is necessary to transplant cells into animal models of disease to allow the cells to 45 
develop fully, make connections with appropriate neuronal inputs and outputs, and display their full 46 
mature phenotype. Indeed, although there are many reports of stem cells being manipulated to 47 
express specific neuronal phenotypes in vitro, very few have shown convincing comprehensive 48 
behavioural efficacy in animal models. Furthermore, assessments must be made to ensure that the 49 
donor cell populations do not contain small numbers of cells which may be capable of tumour 50 
formation. 51 
There are practical issues associated with transplanting human cells into the rodent brain. Although 52 
the brain is recognised as a relatively immune privileged site, it is clear that this is not absolute [13] 53 
and human cells in the rat brain will be rejected over a period of approximately three weeks without 54 
effective modulation of the host immune response [14].  55 
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Commonly used methods of immunosuppression 56 
Immunosuppressant drugs such as Cyclosporine A (CsA), Tacrolimus (FK-506) and Sirolimus 57 
(Rapamycin) are commonly used to promote survival of xenografts in rodent hosts. Using one or a 58 
combination of these drugs or additional compounds can promote survival of human cells 59 
transplanted into the CNS and may be used to prevent xenograft rejection. Immunosuppression with 60 
daily injections of CsA is frequently used in rodent hosts. We have found up to 75-80% survival of 61 
neural xenografts in rat hosts immunosuppressed with CsA for up to a maximum of 20 weeks post-62 
transplantation [15]. Variability in xenograft survival with the same treatment has been reported in 63 
some studies [16, 17], suggesting inconsistencies amongst different host animals and following the 64 
transplantation of different cell types. In particular, although reliably promoting the survival of 65 
human xenografts in the rat brain, we have found the same treatment to be much less reliable in 66 
promoting survival of human transplants in the mouse brain [18] and it is possible that the use of an 67 
increased dose of CsA may be required in this species [17]. CsA treatment demands daily injections 68 
that are stressful to the animal and, with long term use, result in severe adverse side effects 69 
including renal toxicity [19, 20]. Although immunosuppressive treatment is useful for relatively short 70 
term evaluation of graft survival and functional improvement, beyond 16 weeks animal health 71 
begins to deteriorate, precluding functional testing up to full differentiation of transplanted human 72 
cells, which can take approximately four times longer than rodent cells to reach maturity [21, 22]. 73 
Thus realising the true potential of the cells is prevented in this model. 74 
There have been a number of reports of successful tolerance to transplants following blocking of 75 
costimulatory molecules. In a recent study in adult murine hosts, three costimulatory receptor 76 
blocking antibodies (CTLA4-Ig, Anti-LFA-1 and anti-CD40L) were administered at 0, 2, 4 and 6 days 77 
post-transplantation to induce tolerance to xenogeneic human ESC and iPSC derived transplants 78 
[23]. This treatment successfully prevented rejection compared to no treatment or tacrolimus and 79 
sirolimus treatment. Mouse hosts were tolerant to donor cells, exhibiting T cell anergy and no 80 
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detrimental effects on the hosts’ immunity to other cell types were observed [23]. Although offering 81 
a potential method of avoiding immune rejection; survival so far has only been demonstrated up to 82 
8 weeks post transplantation [23]. 83 
Immune compromised rats or mice are common transplant hosts, since they lack the ability to 84 
mount an immune response to xenografted tissues. A number of useful host models exist, in both 85 
rats and mice, for the assessment of donor cell differentiation and integration. The long term 86 
assessment of grafted cells in vivo is necessary to investigate any changes which may not be 87 
detected in short term survival studies afforded by immunosuppressant drug treatments. To this 88 
end, the phenotype of transplanted human PFC- and ESC- derived cells has been investigated in vivo 89 
by several groups using athymic nude rats [24-26]. For example, Aubry and colleagues transplanted 90 
human ESC-derived striatal progenitors into immunocompetent hosts treated with conventional 91 
immunosuppression to assess short term graft survival, and into immunodeficient hosts to study 92 
long term cell maturation and integration [27]. Positive results regarding their differentiation 93 
protocol were identified in the short term, however longer term assessment in nude rats revealed 94 
overgrowth by around 2 months post-transplantation [27]. This would not have been identified with 95 
only short term assessment of graft development, thus highlighting the value of a model which 96 
permits adequate assessment of the maturation of grafts in the long term. Numerous 97 
immunodeficient mouse models also exist including; severe combined immunodeficient (SCID) mice 98 
and Rag1 or Rag2 knockout mice; which lack mature B and T lymphocytes respectively [28, 29] thus 99 
tolerating human transplants without rejection. 100 
However, histological assessment of the graft is not by itself sufficient, and it is important that 101 
evaluation of grafts also includes functional assessment. Due to their susceptibility to infection and 102 
vulnerability with repeated handling, immune compromised hosts are problematic for behavioural 103 
testing. 104 
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Another strategy for achieving xenograft survival is to transplant into the early neonatal period while 105 
the immune system is still immature and before the circulation of mature T cells [30]. Neural 106 
xenotransplants, e.g. of mouse or human tissue are known to survive long term in the neonatal rat 107 
brain when delivered up to 8 days of age, although beyond this point transplants are rejected [31, 108 
32] due to maturation of the host immune system. Although the survival of such grafts is unstable, 109 
with a peripheral immunological challenge of an i.p. injection of xenogeneic donor cells or damage 110 
to the blood brain barrier (BBB) resulting in rejection [33], this can provide a useful model for testing 111 
donor cells, allowing in vivo assessment of safety and differentiation of human donor cells in the 112 
rodent brain or retina [34-36]. As discussed later however, the privilege of neonatal transplant 113 
survival has not been replicable in mouse hosts [37]. The neonatal brain cannot be considered to be 114 
comparable to the adult brain, since it provides a more permissive environment with the presence of 115 
more developmental signals. Findings may therefore not be representative of the therapeutic 116 
situation, in which immature cells are delivered to the adult brain. 117 
Although these methods can provide a number of potential approaches for allowing the survival of 118 
human xenografts in rodent disease models, none provide a solution in which full graft maturation 119 
and functional efficacy of transplanted cells may be assessed long term. Therefore an alternative 120 
method is required for adequate testing of potential human donor cell types for transplantation. 121 
  122 
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Neonatal desensitisation as a method for assessing xenografts in the CNS 123 
Cells implanted to the early neonatal rat brain appear to be recognised as “self” and are not rejected 124 
even once the immune system has matured [31, 32]. Based on this phenomenon we explored 125 
whether injecting human cells peripherally in the early neonatal period would allow the survival of 126 
similar cells subsequently transplanted into the brain in adulthood. We demonstrated that an 127 
intraperitoneal (i.p.) injection of a suspension of human PFCs from the developing cortex hPF(ctx) 128 
into a neonatal rat promotes the survival of a subsequent striatal transplant of human PF brain 129 
without further immunosuppression [15]. A schematic of this method is outlined in Figure 1. 130 
Neonatal injections were found to provide optimum survival when delivered between postnatal day 131 
(P)0 and P5; those injected at P10 or as adults did not support the survival of subsequent neural 132 
transplants. Crucially, survival of human cells was demonstrated until at least 40 weeks post-133 
transplantation following desensitisation and transplantation with a range of different tissue types. 134 
Graft survival rates in desensitised hosts were also found to be comparable to hosts treated daily 135 
with CsA (~62-87% and 75-77% respectively, see Table 1), although survival in CsA 136 
immunosuppressed hosts could only be assessed up to 12-16 weeks due to poor health of the 137 
animals [15]. 138 
The mechanisms by which neonatal desensitisation protects adult neural xenografts from rejection 139 
by the host immune system are currently unclear. A similar phenomenon has been previously 140 
described with the induction of neonatal allograft tolerance in mice [38, 39]. Allograft tolerance has 141 
been achieved in mice following the injection of spleen [40, 41], liver [42], or bone marrow cells [43] 142 
in the neonatal period, in the same way as we have demonstrated with neural xenografts [15]. It is 143 
thought that the induction of neonatal tolerance requires the persistent presence of donor antigen 144 
during the neonatal period to expose the developing immune system to donor cells during the 145 
determination and recognition of self-antigens, resulting in recognition of both donor and host 146 
tissues as self [44]. However since the cells injected into neonatal rats for neonatal desensitisation 147 
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are from a different foetal donor to those used for adult transplants, much more variability will exist 148 
between the donor antigens to which the developing immune system is exposed and those which 149 
are delivered to the adult host. No tolerance to a specific antigen can therefore be assumed, making 150 
the mechanisms behind effective desensitisation to neural tissue transplants from a range of donors 151 
unclear.   152 
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Neonatal desensitisation in the rat host 153 
The desensitisation method is now routinely and reliably used for transplantation experiments in our 154 
lab to test the maturation and functional efficacy of human xenografts in rodent models of both PD 155 
and HD (summarised in Table 2). In the majority of cases host animals were injected neonatally (i.p.) 156 
with a suspension of 1x105 hPF(ctx), since this is the most abundantly available hPF tissue type. 157 
Successful application has been demonstrated in both Sprague Dawley (SD) and Lister Hooded (LH) 158 
rat hosts using lesion models of both PD and HD. Survival of hPF(ctx), hPF(WGE), ventral 159 
mesencephalon (hVM), and human embryonic stem cell (hESC)-derived neurons have all been found 160 
following desensitisation with hPF(ctx), and survival is comparable to that of transplants in hosts 161 
immunosuppressed daily with CsA. However, human foetal cells are not widely available and thus it 162 
was important to assess whether human cells of a non-foetal origin were capable of inducing 163 
desensitisation. As can be seen from Table 2, desensitisation was successfully induced following 164 
neonatal injections of non-foetal cells such as FNP-derived and ES-derived neuronal progenitors, and 165 
even non-neural cells. 166 
There is some variability in the percentage of grafts surviving in both desensitised and CsA treated 167 
hosts that is as yet unexplained.  Some of this may be due to poor viability of the donor cells, but it 168 
may also be the case that a strong mismatch between the cells used for desensitisation and those 169 
subsequently transplanted in adulthood, so that the latter are not adequately protected. For 170 
example, Table 2 shows that in host animals that were desensitised with hPF(ctx) cells from embryo 171 
A and subsequently then grafted with cells from embryo C, the survival of grafts is poorer than when 172 
the grafts are from embryo D, suggesting that A and C may be less well matched than A and D. 173 
Currently the numbers of animals included in such comparisons is too low to draw firm conclusions, 174 
but this sort of analysis may provide important insight into the mechanisms behind neonatal 175 
desensitisation and deserves further investigation. An additional caveat of these studies which may 176 
have caused variability in the data from desensitisation experiments is the use of outbred rat stocks 177 
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(SD and LH). Differences in MHC haplotype between host animals may result in different host 178 
responses to transplanted human donor cells. These studies therefore require replication using an 179 
inbred rat strain to reduce this variability and allow firmer conclusions to be reached from the data. 180 
An inbred strain that is suitable for behavioural studies would be optimal, in order to provide hosts 181 
which can be successfully desensitised, transplanted and undergo a battery of motor and cognitive 182 
behavioural tasks. 183 
A number of other groups have used desensitisation to promote survival of various human cell types 184 
in animal models of disease. For example, rat hosts with induced knee cartilage defects were 185 
successfully desensitised with 1x105 hESC-derived mesenchymal stem cells (hESC-MSC) [45]. These 186 
hosts could support survival of a collagen bilayer scaffold seeded with hESC-MSC for at least 8 weeks 187 
post-transplantation, whereas animals that were not desensitised neonatally showed increased T 188 
cell infiltration and transplant rejection [45]. Another group aimed to determine whether human 189 
Müller glia stem cells have the potential to differentiate into retinal ganglion cells (RGC) when 190 
transplanted into a LH rat model of RGC depletion [46]. In order to test this, survival of transplanted 191 
human Müller glia stem cells was achieved using a combination of neonatal desensitisation with 192 
1x105 cells of the same type, and daily administration of oral CsA, prednisolone and azathioprine. 193 
Hosts were transplanted at 3-4 weeks of age with undifferentiated stem cells or RGC precursors, 194 
both of which were found to survive under these conditions up to 4 weeks post transplantation [46]. 195 
Subsequently this group has also successfully assessed the survival of photoreceptors derived from 196 
hMSC following transplantation into rats, with the use of the same desensitisation and 197 
immunosuppression method [47]. 198 
Although neonatal desensitisation has been successfully used to promoting survival of various 199 
human cell types in rat hosts, there have also been some negative reports [16, 48]. Human cord 200 
blood derived neural stem cells (HUCB-NSC) were used for desensitisation of Wistar rats at birth. 201 
Neural transplants of HUCB-NSC were delivered to 6 week old desensitised hosts and survival 202 
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assessed at various time-points post transplantation. The presence of human cells was confirmed at 203 
early time-points (1 and 3 days after transplantation), and a substantial decrease in cell number 204 
reported subsequently, (7 and 14 days) and no cells detected 21 days after transplantation [48]. As 205 
survival was shown in rag2-/- mice for 3 weeks and reported for up to 5 weeks, the authors 206 
concluded that neonatal desensitisation was not successful using this cell type. In a subsequent 207 
publication, this group also reported the failure of neonatal desensitisation to promote survival of 208 
HUCB-NSC beyond 21 days following transplantation into infarcted rats [16]. In this case, however, 209 
poor graft survival was also found in control hosts treated with either CsA or a triple 210 
immunosuppression regime (CsA, azathioprine and methylprednisolone) [16]. Thus, this study does 211 
not conclusively demonstrate ineffectiveness of neonatal desensitisation, but may be simply 212 
indicative of a problem with survival of this donor cell type, or survival within this lesion model in 213 
this specific strain of rat. This highlights the need for adequate demonstration of survival of human 214 
donor cells in the immunocompetent adult host brain (e.g. immunosuppressed adult rats of the 215 
same strain), in order to define whether the failed graft is a result of immune rejection or that the 216 
cells have failed to survive for some other reason.  217 
 218 
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Neonatal desensitisation of mouse hosts 219 
Although successful neonatal desensitisation of rat hosts has been demonstrated on numerous 220 
occasions, the same has not been shown in mice. Our initial studies were all carried out in rats, as we 221 
have more commonly used these for transplant hosts in order to take advantage of a wide range of 222 
behavioural tests optimised in rat models of PD and HD, and as we have regularly achieved decent 223 
survival of large within and between species transplants under appropriate immunosuppression. 224 
However, using mice as long term transplant hosts would allow the use of a wide range of available 225 
transgenic models that are not currently available in rats. In addition to models of 226 
neurodegeneration, a number of mouse models exist with modified immune systems, which would 227 
provide tools to investigate the mechanisms underlying neonatal desensitisation to human 228 
xenografts. 229 
To date we have carried out a number of experiments to investigate the possibility of successful 230 
neonatal desensitisation of mouse hosts with little success, which have been reported in more detail 231 
elsewhere [18]. Initial experiments were carried out using the standard neonatal desensitisation 232 
protocol optimised previously for rat hosts [49] in CD-1 mice. However, in addition to poor survival 233 
of hPF(ctx) in the desensitised mouse hosts, there was also poor survival in immunosuppressed 234 
(daily CsA treated) mice [18] suggesting that there is a general problem of neural graft survival in the 235 
mouse. Again the use of outbred mice is of additional concern here, with a likely increase in the 236 
variability of transplant survival. Attempts to improve graft survival were made through 237 
modifications to the transplant protocol. These included transplanting an increased number of 238 
donor cells (5x105 vs 3x105), and transplantation at different time-points following a quinolinic acid 239 
lesion, or into the intact striatum, in order to avoid the delivery of cells into a compromised 240 
environment. No improvement in survival was seen in any of these conditions. Varying the number 241 
of cells injected neonatally to improve neonatal desensitisation also proved unsuccessful [18]. The 242 
fact that survival in desensitised mice hosts was comparable to untreated hosts (~15% for both), 243 
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suggests that desensitisation was not successful in mice.  However, as only 50% of grafts in hosts 244 
receiving a conventional immunosuppressant (CsA) survived it is not possible to conclusively 245 
determine whether or not desensitisation or other factors are responsible for the poor survival [18]. 246 
These findings are in line with research from other groups, which has also shown poor translation of 247 
neonatal desensitisation to mice using various host strains and donor cell types [37, 48]. Mattis et al 248 
performed a systematic investigation of neonatal desensitisation in three different strains of mice 249 
(both inbred and outbred) using three human stem cell types [37]. Both transgenic HD and wild type 250 
(WT) mice received i.p. injections on P2-3 of hPF-derived neural progenitor cells or ESC-derived NPCs 251 
and subsequently received bilateral striatal transplants of the same cell type at 5-10 weeks of age. 252 
Rejection of both cell types was seen at 6 weeks post-transplantation with dense infiltration of 253 
activated microglia and a lack of donor cells at the transplant site [37]. Treatment with CsA in 254 
desensitised and non-desensitised hosts was found to improve survival, although a reduction in the 255 
size of the transplants and the presence of microglial inflammation was still observed. Similar results 256 
were obtained using an inbred mouse strain (C57/BL6) with a neonatal injection of hESC-derived 257 
NPC at P5 followed by a transplant of the same cells at 2 months. No grafts were found to survive in 258 
untreated or desensitised hosts at 2 or 6 weeks post-transplantation [37]. 259 
Along with their experiments on desensitisation in rats, Janowski et al also tested whether mouse 260 
hosts (BALB/c) could be successfully desensitised to luciferase expressing human glial-restricted 261 
precursor (hGRP) cells derived from foetal brain [48]. The use of this line allowed detection of 262 
injected cells for both desensitisation and transplantation with in vivo bioluminescence imaging 263 
(BLI). The authors found a rapid reduction on BLI signal within a few days following desensitisation 264 
(<5 days) suggestive of elimination of peripherally injected cells. Following neural transplantation a 265 
reduction in BLI signal was again observed and was undetectable after 2 weeks in adult desensitised 266 
and naïve BALB/c mouse hosts. Transplants of hGRP cells delivered to adult rag2-/- hosts (n = 5), 267 
were found to survive well up to 3 weeks post-transplantation, however longer time-points are 268 
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necessary to determine whether these cells would survive long term. Dense infiltration of CD45+ 269 
immune cells was found in both desensitised and naïve hosts following sacrifice at 2 weeks post 270 
transplantation suggesting the loss of transplanted cells was due to rejection through the host 271 
immune system [48]. 272 
The rapid signal loss observed following neonatal i.p. injections in this study is interesting [48]. 273 
Although we do not know the mechanisms by which desensitisation of rats is produced, we may 274 
assume that the presence of donor cells for presentation to the immature neonatal immune system 275 
during development is necessary, and that this may not be possible if cells are rapidly rejected 276 
following neonatal injection. Support for this notion comes from Mattis et al’s experiments; in which 277 
neonatal transplants of luciferase expressing human iPSC-derived neural precursor cells (iPSC-NPCs) 278 
to the neonatal mouse brain declined from approximately 9 days post transplantation with no cells 279 
remaining by 28 days [37]. These results were subsequently confirmed with histological analysis. The 280 
survival of the same cells was confirmed in vitro for several weeks, showing these cells to be healthy, 281 
and survival was also confirmed in neonatal immunodeficient (NOD SCID) mice. Additionally, 282 
transplants of hFNPs were also rejected in the neonatal mouse striatum, with increased 283 
immunoreactivity to the microglial marker Iba1 [37]. These findings differ to neonatal rat neural 284 
transplants of human cells, which have been consistently shown to survive long term [24, 25, 31, 36]. 285 
The findings of these two studies therefore suggest that, in contrast to rat hosts, xenogeneic donor 286 
cells are rapidly rejected in both the CNS and the periphery of neonatal mice. This may indicate that 287 
the immune system develops earlier in the postnatal period than in rats and is more developed by 288 
birth, or that it is simply more readily equipped for the rejection of human donor cells. 289 
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Xenograft rejection; a difference between rat and mouse hosts. 290 
Numerous studies have investigated the rat host immune response to neural xenografts of mouse 291 
[50], porcine [51, 52] and human tissue. Some studies have been carried out to characterise the 292 
rejection of porcine tissue transplants in mice [17, 53, 54], however less work has been conducted 293 
specifically investigating the mouse host response to transplanted human cells. Thus, much neural 294 
transplant work has assumed a similarity between mice and rats as transplant hosts. In comparing 295 
the rat and mouse host immune response to transplants of porcine cells, Larsson et al found a much 296 
faster, more severe response from the mouse hosts [17]. We have recently compared the survival of 297 
human donor cells (hCTX) transplanted unilaterally into the striatum of QA lesioned rat (SD) and 298 
mouse (CD-1) hosts receiving no immunosuppression or daily CsA (Roberton, VH; unpublished data). 299 
At 10 days post-transplantation all grafts remained present in both CsA treated and untreated rat 300 
hosts. However rejection in mouse hosts was much more rapid, with only 50% of transplants 301 
remaining in both the untreated hosts and those receiving daily injections of CsA after 10 days. 302 
Findings discussed here regarding human to mouse xenografts are in line with this, showing a rapid 303 
clearance of human donor cells both in the periphery and the CNS [18, 37, 48]. The use of neonatal 304 
hosts does not avoid this, with cells injected intraperitoneally being cleared by around 5 days [48], 305 
and striatal transplants reducing in size from 9 days showing complete rejection by 21-28 days. In all 306 
cases dense infiltration of activated microglia is observed [18, 37]. It has been reported that higher 307 
doses of CsA may be required to successfully promote survival of xenografts in mouse hosts, 308 
although care is needed regarding the side effects [17]. Indeed, in all mouse experiments we have 309 
conducted, a dose of 10mg/kg daily via i.p. injection has been administered as we have found this to 310 
be successful in rat hosts [18]. Interestingly, Mattis et al reported survival of xenografts in CsA 311 
treated mouse hosts, albeit with some reduction in graft size up to 6 weeks post-transplantation. 312 
They administered 15mg/kg i.p daily, thus this may explain differences observed in survival between 313 
these studies [37]. Ultimately until issues with inconsistent xenograft survival in mouse hosts and the 314 
mechanisms behind successful neonatal desensitisation can be resolved it cannot be determined 315 
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whether the neonatal desensitisation protocol can be modified for successful application in mouse 316 
hosts. 317 
 318 
Conclusions and future perspective 319 
To date, neonatal desensitisation has been reliably demonstrated to promote survival of a range of 320 
human cell types in various rat models whilst avoiding the limitations associated with other 321 
immunosuppressant methods. It allows xenograft survival to a comparable extent to conventional 322 
immunosuppressant drugs, but for substantially longer [15, 45-47]. Desensitisation of rat hosts will 323 
therefore permit long term studies of graft maturation and functional outcomes that have not 324 
previously been possible. The method has not been successfully translated into mouse hosts, and 325 
the investigation of desensitisation in the mouse has revealed a number of fundamental differences 326 
between mice and rats in terms of the immune response to neural xenografts in both neonates and 327 
adults [18, 37, 48]. It will be important to unravel the mechanism underlying neonatal 328 
desensitisation, both to understand whether it can be modified for use in the mouse and to facilitate 329 
optimisation of the method in rats.  330 
 331 
Executive summary 332 
Why is long term assessment of human neural grafts in rodent hosts needed? 333 
 Current immunosuppression methods are not adequate for full assessment of graft 334 
maturation and the measurement of functional improvements following transplantation. 335 
Neonatal desensitisation as a method for assessing xenografts in the CNS 336 
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 Neonatal desensitisation takes advantage of the immaturity of the immune system of 337 
neonatal rats, promoting the long term survival of subsequent human xenografts in adult rat 338 
hosts. 339 
Neonatal desensitisation in the rat host 340 
 Effective desensitisation of rat hosts has been achieved in a range of models for as long as 341 
40 weeks after transplantation. 342 
 Poor xenograft survival in desensitised rat hosts may be related to, therefore adequate 343 
survival in immunosuppressed hosts must be demonstrated. 344 
Neonatal desensitisation of mouse hosts 345 
 Successful desensitisation of mouse hosts has not yet been demonstrated, and further study 346 
is needed to resolve the variability in xenograft survival in mouse hosts. 347 
 348 
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Cells used for neonatal 
desensitisation 
Cells used for subsequent 
adult graft 
Time post-transplant (weeks) Number of grafts surviving (%) 
mPF(WGE) mPF(WGE) 10 11/15 (73%) 
mFNP mFNP 10 11/13 (85%) 
hPF(ctx) hPF(ctx) 40 48/55 (87%) 
hPF(WGE) hPF(WGE) 25 10/15 (66%) 
hFNP hFNP 12 10/13 (77%) 
hES-N hES-N 12 9/12 (75%) 
hFNP hPF(ctx) 12 11/13 (85%) 
hPF(ctx) hFNP 12 11/14 (79%) 
hLiver hPF(ctx) 12 8/13 (62%) 
hPF(ctx) hPFWGE 10 19/23 (83%) 
None hPF(ctx) 12 0/9 (0%) 
None hPF(WGE) 2 0/7 (0%) 
None, but given CsA hPF(WGE) 12 7/9 (77%) 
None, but given CsA hFNP 12 6/8 (75%) 
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Table 1 Summary of data in Kelly et al. (2009) [14] to show survival of human xenografts in adulthood where the neonate has been injected with cells from 349 
a similar (concordant) or different (discordant) origin. Transplant hosts in all experimental groups were SD rats. Graft survival is comparable to that seen in 350 
CsA-treated hosts and no graft survival is seen in host receiving no immune-modulatory treatment. h=human, m=mouse, PF(ctx) = primary foetal cortex, 351 
PF(WGE) = whole ganglionic eminence, FNP = foetal neural precursors derived from foetal cortical tissue, hES-N = human ESChLiver = human liver, CsA = 352 
Cyclosporine A 353 
 354 
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Strain 
Cells used for 
desensitisation 
Sample used for 
desensitisation 
Lesion 
Tissue 
Transplanted 
Sample used 
for adult graft 
Surviving (%) Time post TX 
SD hPF(ctx) A QA hPF(ctx) C 3/7 (42.86%) 6 weeks 
SD hPF(ctx) A QA hPF(ctx) C 1/3 (33.33%) 9 weeks 
SD hPF(ctx) A QA hPF(ctx) D 4/4 (100.00%) 9 weeks 
SD CsA - QA hPF(ctx) C 2/2 (100.00%) 6 weeks 
LH hPF(ctx) A QA hPF(ctx) C 1/3 (33.33%) 6 weeks 
LH hPF(ctx) A QA hPF(ctx) D 3/3 (100.00%) 9 weeks 
LH CsA - QA hPF(ctx) C 3/4 (75.00%) 6 weeks 
LH CsA - QA hPF(ctx) D 3/3 (100.00%) 9 weeks 
SD hPF(ctx) B QA hPF(ctx) E 3/8 (37.50%) 6 weeks 
SD CsA - QA hPF(ctx) E 2/2 (100.00%) 6 weeks 
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Table 2 Previously unpublished data using neonatal desensitisation of rat hosts to promote survival 355 
of hPF(ctx) transplants. All hosts were desensitised with 1x105 cells injected i.p. and subsequently 356 
transplanted unilaterally with 5x105 cells. SD = Sprague Dawley; LH = Lister Hooded; hPF(ctx) = 357 
human primary foetal cortical cells; hVM = human primary foetal ventral mesencephalon; QA = 358 
Quinolinic acid lesion; 6-OHDA = 6-hydroxydopamine lesion; TX = Transplant 359 
 360 
 361 
 362 
Figure 1 The neonatal desensitisation protocol. hPF(ctx) was used to inoculate early neonatal rat 363 
pups by i.p. injection. The animals were allowed to survive to maturity and then received a neural 364 
transplant of similar human PF(ctx) cells from a separate fetal sample. From Kelly et al (2009). 365 
 366 
 367 
 368 
 369 
 370 
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